पेटेंट कार्यालय
शासकीय जर्नल

OFFICIAL JOURNAL
OF
THE PATENT OFFICE

निर्गमन सं. 02/2026	शुक्रवार	दिनांक: 09/01/2026
ISSUE NO. 02/2026	FRIDAY	DATE: 09/01/2026

पेटेंट कार्यालय का एक प्रकाशन
PUBLICATION OF THE PATENT OFFICE

(12) PATENT APPLICATION PUBLICATION
(19) INDIA
(22) Date of filing of Application :25/11/2025
(21) Application No.202511116840 A
(43) Publication Date : 09/01/2026

(54) Title of the invention : FORMULATION AND EVALUATION OF ORALLY DISINTEGRATING TABLETS OF ONDANSETRON

(51) International classification	:A61P1/08, A61K9/20, A61K47/38, A61K47/12, A61K47/24, A61K47/26, A61K47/14, A61K47/22
(31) Priority Document No	:NA
(32) Priority Date	:NA
(33) Name of priority country	:NA
(86) International Application No Filing Date	: :01/01/1900
(87) International Publication No	: NA
(61) Patent of Addition to Application Number Filing Date	:NA :NA
(62) Divisional to Application Number Filing Date	:NA :NA

(71)**Name of Applicant :**
1)Dr. Navneet Verma
Address of Applicant :Professor, Pharmacy Academy, Faculty of Pharmacy, IFTM University, Moradabad, Uttar Pradesh, Pin Code:244102, India Uttar Pradesh India
2)Rajiv Yadav
3)Dr. Yash Prashar
4)Kumarappan Chidambaram
5)Dr Shalini Kulshrestha
6)Julliyan Dilleban A
7)Dr. Jobin Jose
8)Dr. Abhishek Nagar
(72)**Name of Inventor :**
1)Dr. Navneet Verma
2)Rajiv Yadav
3)Dr. Yash Prashar
4)Kumarappan Chidambaram
5)Dr Shalini Kulshrestha
6)Julliyan Dilleban A
7)Dr. Jobin Jose
8)Dr. Abhishek Nagar

(57) Abstract :
The present invention relates to an improved pharmaceutical composition of ondansetron in the form of orally disintegrating tablets exhibiting rapid disintegration, enhanced stability, improved taste masking, and superior bioavailability. The formulation comprises ondansetron as the active pharmaceutical ingredient, superdisintegrants selected from crospovidone and croscarmellose sodium in optimized ratios, directly compressible excipients including microcrystalline cellulose and mannitol, sweetening agents for taste masking, and suitable lubricants. The tablets are prepared by direct compression method without requiring freeze drying or complex manufacturing processes. The formulation achieves complete disintegration within 30 seconds in the oral cavity, provides immediate release characteristics with more than 90% drug release within 15 minutes, maintains structural integrity during packaging and handling, and masks the bitter taste of ondansetron effectively. The invention addresses the limitations of existing ondansetron formulations by providing a cost effective, patient friendly dosage form particularly suitable for pediatric and geriatric populations experiencing nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions.

No. of Pages : 22 No. of Claims : 10